344510
FTase Inhibitor I
The FTase Inhibitor I controls the biological activity of FTase. This small molecule/inhibitor is primarily used for Cancer applications.
别名:
FTase Inhibitor I, N-[2(S)-[2(R)-Amino-3-mercaptopropylamino]-3-methylbutyl]-Phe-Met-OH, B581
产品名称
FTase Inhibitor I, The FTase Inhibitor I controls the biological activity of FTase. This small molecule/inhibitor is primarily used for Cancer applications.
assay
≥90% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated (hygroscopic)
color
white
solubility
water: 1 mg/mL
DMSO: 5 mg/mL
shipped in
ambient
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Cell permeable: yes
Primary Target
FTase
FTase
Product does not compete with ATP.
Reversible: no
Target IC50: 21 nM against FTase in vitro
Disclaimer
Toxicity: Standard Handling (A)
General description
A potent, cell-permeable inhibitor of farnesyltransferase (FTase) that is about 37-fold more active against FTase (IC50 = 21 nM in vitro) than against geranylgeranyltransferase (GGTase; IC50 = 790 nM). Very resistant to proteolysis.
A potent, cell-permeable, selective, peptidomimetic inhibitor of farnesyltransferase (FTase) that is approximately 37-fold more active against FTase (IC50 = 21 nM in vitro) than against geranylgeranyltransferase (GGTase; IC50 = 790 nM). Very resistant to proteolysis.
Other Notes
Yamaguchi, M., et al. 2004. Stroke35, 1750.
Cox, A.D., et al. 1994. J. Biol. Chem.269, 19203.
Garcia, A.M., et al. 1993. J. Biol. Chem. 268, 18415.
Cox, A.D., et al. 1994. J. Biol. Chem.269, 19203.
Garcia, A.M., et al. 1993. J. Biol. Chem. 268, 18415.
Packaging
Packaged under inert gas
Physical form
Supplied as a trifluoroacetate salt.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Carmen M Deveau et al.
Biochemical pharmacology, 183, 114349-114349 (2020-11-28)
Serotonin neurotransmission is largely governed by the regulation of the serotonin transporter (SERT). SERT is modulated in part by cholesterol, but the role of cholesterol and lipid signaling intermediates in regulating SERT are unknown. Serotonergic neurons were treated with statins
Yusuke Marikawa et al.
Molecular human reproduction, 27(4) (2021-03-08)
Early embryos are vulnerable to environmental insults, such as medications taken by the mother. Due to increasing prevalence of hypercholesterolemia, more women of childbearing potential are taking cholesterol-lowering medications called statins. Previously, we showed that inhibition of the mevalonate pathway
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持